PKA Activator

8-(4-Chlorophenylthio)-cAMP (8CPT-cAMP) is a cell membrane-permeable cAMP analog with excellent membrane permeability, which activates Sgk kinase via phosphorylation mediated by PKA. 8-(4-Chlorophenylthio)-cAMP is hydrolyzed by intracellular enzymes to produce the active metabolite 8CPT-Ade, which induces cortisol synthesis and the expression of steroidogenic protein genes. When used in combination with insulin, 8-(4-Chlorophenylthio)-cAMP enhances the activation of Sgk; it activates the cAMP pathway to promote the proliferation and iodine uptake of thyroid cells. 8-(4-Chlorophenylthio)-cAMP can be used in studies related to metabolism and signal transduction.

8-Bromo-cAMP sodium salt (Standard) is the analytical standard of 8-Bromo-cAMP sodium salt (HY-12306). This product is intended for research and analytical applications. 8-Bromo-cAMP sodium (8-Br-Camp) sodium salt, a cyclic AMP analog, is an activator of cyclic AMP-dependent protein K_inase (PKA). 8-Bromo-cAMP sodium salt has anti-proliferative and apoptotic effects against cancer cells.

6-Bnz-cAMP, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K⁺ channel. 6-Bnz-cAMP does not activate the Epac signaling pathway. 6-Bnz-cAMP inhibits the bTREK-1 K⁺ channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. 6-Bnz-cAMP can be used in studies related to bone tissue repair and regeneration.

Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (GMP) is a Bucladesine sodium (HY-B0764) produced by using GMP guidelines. Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation.